SAFETY DATA SHEET

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Epirubicin Hydrochloride Injection

Product Code(s) PZ00033
Trade Name: Ellence; Farmorubicin; Pharmorubicin; Farmorubicina; Farmorubicine
Chemical Family: Anthracycline

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as Antineoplastic

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Germ cell mutagenicity Category 1B
Carcinogenicity Category 1B
Reproductive toxicity Category 1B

OSHA Classification

Hazards not otherwise classified (HNOC)
Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200
Not applicable

2.2. Label elements

Signal word Danger

Hazard statements
H360FD - May damage fertility. May damage the unborn child
H350 - May cause cancer
H340 - May cause genetic defects

Precautionary Statements - EU (§28, 1272/2008)
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Epirubicin Hydrochloride (CAS #: 56390-09-1)	0.2		260-145-2	Acute Tox.4 (H302) Carc. 1B (H350) Muta. 1B (H340) Repr. 1B (H360FD)RE 1 (H372)	Not classified	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)

				(EC) No. 1272/2008 [CLP]			
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Epirubicin Hydrochloride 56390-09-1	1350	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride, and other chlorine-containing compounds.

Explosion data
Sensitivity to mechanical impact No information available.
Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.
Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Restrict access to work area. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should

	be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions	Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)	Pharmaceutical drug product. Antineoplastic.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits
Refer to available public information for specific member state Occupational Exposure Limits.
Epirubicin Hydrochloride
Pfizer OEL TWA-8 Hr: 0.6 µg/m³
SODIUM CHLORIDE

Latvia	TWA: 5 mg/m³;
Russia	MAC: 5 mg/m³

Pfizer Occupational Exposure Band (OEB) Statement:	The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious disposable protective clothing is recommended if skin contact with drug product

	is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Solution
Physical state	Liquid
Color	Red
Odor	No information available.
Odor threshold	No information available

Property	**Values**
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes
No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity
Reactivity No information available.
10.2. Chemical stability
Stability Stable under normal conditions.
Explosion data
Sensitivity to mechanical impact No information available.
Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions
Possibility of hazardous reactions No information available.

10.4. Conditions to avoid
Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.
10.5. Incompatible materials
Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products
Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes, the developing fetus.
Known Clinical Effects: Adverse effects most commonly reported in clinical use include local irritation, nausea, vomiting, inflammation of the mouth (stomatitis), facial flushing, conjunctivitis of the eye, tearing (lachrymation), loss of hair and discoloration of skin. Effects on blood and blood-forming organs have also occurred.

Acute toxicity Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation Based on available data, the classification criteria are not met.
Skin corrosion/irritation Based on available data, the classification criteria are not met.
Respiratory or skin sensitization Based on available data, the classification criteria are not met.
STOT - single exposure Based on available data, the classification criteria are not met.
STOT - repeated exposure Based on available data, the classification criteria are not met.
Reproductive toxicity Based on available data, the classification criteria are not met.
Germ cell mutagenicity Based on available data, the classification criteria are not met.
Carcinogenicity Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)
SODIUM CHLORIDE
Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m^3
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Epirubicin Hydrochloride

Rat Oral LD 50 1350 mg/kg
Rat Para-periosteal LD50 17 mg/kg
Mouse Oral LD50 > 2000 mg/kg
Mouse Intravenous LD50 31.5 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Epirubicin Hydrochloride	= 1350 mg/kg (Rat)	-	-

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Epirubicin Hydrochloride

6 Week(s) Rabbit Intravenous 1 mg/kg/day LOAEL Kidney, Heart
6 Week(s) Dog Intravenous 0.4 mg/kg/day LOAEL Kidney
13 Week(s) Rat Intravenous 0.128 mg/kg/day LOAEL Blood, Male reproductive system, Heart, Kidney, Thymus
13 Week(s) Dog Intravenous 0.64 mg/kg/day LOAEL Blood, Heart, Gastrointestinal system, Male reproductive system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Epirubicin Hydrochloride

Reproductive & Fertility Rat Oral 0.3 mg/kg/day LOAEL Fertility
Reproductive & Fertility Rat Oral 0.1 mg/kg/day NOAEL Fertility
Embryo / Fetal Development Rat Intravenous 0.8 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rat Intravenous 2 mg/kg/day LOAEL Teratogenic, Fetotoxicity
Embryo / Fetal Development Rat Intravenous 0.2 mg/kg/day NOAEL Teratogenic, Fetotoxicity
Embryo / Fetal Development Rabbit Intravenous 1 mg/kg/day LOAEL Embryotoxicity, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Epirubicin Hydrochloride

Bacterial Mutagenicity (Ames) Positive
Mammalian Cell Mutagenicity HGPRT Positive
Chromosome Aberration Human Lymphocytes Positive
Chromosome Aberration Mouse Lymphoma Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Epirubicin Hydrochloride

1 Year(s) Rat Intravenous 3.6 mg/kg LOAEL Tumors, Female reproductive system
18 Month(s) Rat Intravenous 0.5 mg/kg LOAEL Tumors

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.
PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

Epirubicin Hydrochloride

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	260-145-2

National regulations

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)
Not applicable

TRGS 905 Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018	Not applicable
Storage of Hazardous Material	Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20	Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed H350 - May cause cancer H340 - May cause genetic defects H360FD - May damage fertility. May damage the unborn child H372 - Causes damage to organs through prolonged or repeated exposure

Data Sources:	Publicly available toxicity information. Pfizer proprietary drug development information.
Reason for revision	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 16 - Other Information.
Revision date	13-Jun-2025
Prepared By	Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.